AstraZeneca COVID-19 vaccine to US Phase 3 trial
According a press release and a recent article from Drug Topics, AstraZeneca’s investigational vaccine candidate AZD12222 expanded into a phase 3 clinical trial.
The trial is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
Up to 30,000 adults aged 18 years or older will be enrolled to assess the safety and immunogenicity of AZD1222, which was co-invented by the University of Oxford and Vaccitech.
For more information, read the full article from Drug Topics.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
